EZZ Life Science Holdings Ltd. reported an EPS of AU$0.027 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.922%.

0 Followers

EZZ Stock Chart & Stats

Advanced Chart >

Day’s RangeAU$0 - AU$0

52-Week RangeAU$0.43 - AU$0.92

Previous CloseAU$0.89

Volume1.05K

Average Volume (3M)66.05K

Market Cap

AU$39.77M

Enterprise ValueAU$29.17M

Total Cash (Recent Filing)AU$10.46M

Total Debt (Recent Filing)AU$104.57K

Price to Earnings (P/E)10.9

Beta0.09

Next Earnings

Aug 27, 2024

EPS EstimateN/A

Last Dividend Ex-Date

Oct 30, 2023

Dividend Yield2.25%

Share Statistics

EPS (TTM)0.08

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. Volume66,049

Standard DeviationN/A

R-SquaredN/A

AlphaN/A

Financial Highlights & Ratios

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EZZ Life Science Holdings Ltd. News

PremiumCompany Announcements

EZZ Life Science Reports Record Quarterly Growth

8d ago

EZZ

PremiumCompany Announcements

EZZ Life Science Issues New Shares

17d ago

EZZ

PremiumCompany Announcements

EZZ Life Science Holdings Gears Up for Expansion

17d ago

EZZ

PremiumCompany Announcements

EZZ Life Science Announces New Share Issue

21d ago

EZZ

See More AU:EZZ News >

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.20% Insiders

0.00% Mutual Funds

0.00% Other Institutional Investors

99.80% Public Companies and

Individual Investors

Detailed Ownership Overview >

EZZ FAQ

What was EZZ Life Science Holdings Ltd.’s price range in the past 12 months?

EZZ Life Science Holdings Ltd. lowest share price was AU$0.43 and its highest was AU$0.92 in the past 12 months.

What is EZZ Life Science Holdings Ltd.’s market cap?

Currently, no data Available

When is EZZ Life Science Holdings Ltd.’s upcoming earnings report date?

EZZ Life Science Holdings Ltd.’s upcoming earnings report date is Aug 27, 2024 which is in 117 days.

How were EZZ Life Science Holdings Ltd.’s earnings last quarter?

EZZ Life Science Holdings Ltd. released its earnings results on Feb 29, 2024. The company reported AU$0.027 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.027.

Is EZZ Life Science Holdings Ltd. overvalued?

According to Wall Street analysts EZZ Life Science Holdings Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does EZZ Life Science Holdings Ltd. pay dividends?

EZZ Life Science Holdings Ltd. pays a Annually dividend of <AU$0.01 which represents an annual dividend yield of 2.25%. See more information on EZZ Life Science Holdings Ltd. dividends here

What is EZZ Life Science Holdings Ltd.’s EPS estimate?

EZZ Life Science Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does EZZ Life Science Holdings Ltd. have?

EZZ Life Science Holdings Ltd. has 44,413,200 shares outstanding.

What happened to EZZ Life Science Holdings Ltd.’s price movement after its last earnings report?

EZZ Life Science Holdings Ltd. reported an EPS of AU$0.027 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.922%.

Which hedge fund is a major shareholder of EZZ Life Science Holdings Ltd.?

Currently, no hedge funds are holding shares in AU:EZZ

---

EZZ Life Science Holdings Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

24.87%

Trailing 12-Months

Asset Growth

35.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

EZZ Life Science Holdings Ltd.

EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The firm is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide.

---